Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

UNM

Unum cedes $3.8B LTC reserves in coinsurance deal

Unum Group said Monday it will cede $3.8 billion of long-term care statutory reserves to Fortitude Re in a coinsurance deal that cuts its remaining LTC reserve exposure by more than a quarter.

The transaction covers about 50,000 individual LTC policies and represents 26% of Unum’s total LTC statutory reserves and 52% of its individual LTC reserves as of March 31, 2026. After the deal closes, Unum expects its remaining LTC statutory reserves to fall to about $11.0 billion.

The company said roughly 70% of those remaining reserves will back group LTC policies, which have more basic benefit structures than individual policies.

The new reinsurance pact follows a similar transaction Unum announced in 2025. Together, the two deals will have reinsured more than $7 billion of LTC statutory reserves and reduced Unum’s total LTC statutory reserves by about 40%.

Unum said it will retain administration of the reinsured business, including claims handling and premium rate increase management. Fortitude Re will retrocede biometric risk on the block to a highly rated global reinsurer.

The company said the transaction is expected to leave it with year-end 2026 holding company liquidity of $1.5 billion to $2.0 billion, leverage of about 25%, and RBC of 400% to 425%.

Unum estimated the reinsured block at approximately $4.5 billion of best estimate reserves. The deal is expected to close during 2026. The market has reacted to these announcements by moving the company's shares -4.3% to a price of $88.365. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS